Therapeutic vaccines for melanoma: progress and problems

Melanoma vaccines, which have been under development for many years, are being refined as a result of the knowledge gained from practical testing. We now have a more complete understanding of their mode of action and the problems that remain to be solved. There are points to recommend both crude and...

Full description

Saved in:
Bibliographic Details
Published in:Trends in biotechnology (Regular ed.) 1996-09, Vol.14 (9), p.349-355
Main Authors: Jones, Vicky E., Mitchell, Malcolm S.
Format: Article
Language:English
Subjects:
Antigens, Neoplasm - isolation & purification
Antineoplastic agents
Biological and medical sciences
Biotechnology
Biotechnology - trends
Cancer Vaccines - administration & dosage
Cancer Vaccines - isolation & purification
Cancer Vaccines - therapeutic use
Epitopes - isolation & purification
Humans
Immune Tolerance
Immunotherapy
Immunotherapy, Active
Medical sciences
Melanoma - immunology
Melanoma - therapy
Pharmacology. Drug treatments
T-Lymphocytes - immunology
Tumor Cells, Cultured
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Melanoma vaccines, which have been under development for many years, are being refined as a result of the knowledge gained from practical testing. We now have a more complete understanding of their mode of action and the problems that remain to be solved. There are points to recommend both crude and pure vaccines — each have specific advantages, but both require further development. Isolation of relevant peptide epitopes, addition of co-stimulatory molecules, the development of novel vehicles for vaccine delivery and improved vaccine adjuvants, and the problem of tumor-induced immunosuppression are among the issues for future study.
ISSN:0167-7799
1879-3096
DOI:10.1016/0167-7799(96)10045-7